[
  {
    "ts": "2025-12-08T05:32:07+00:00",
    "headline": "Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-prefers-buying-eli-053207796.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7d1562e3-f741-3e7a-bdb9-404fbcbe7fd1",
      "content": {
        "id": "7d1562e3-f741-3e7a-bdb9-404fbcbe7fd1",
        "contentType": "STORY",
        "title": "Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]",
        "pubDate": "2025-12-08T05:32:07Z",
        "displayTime": "2025-12-08T05:32:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-prefers-buying-eli-053207796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-prefers-buying-eli-053207796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T14:21:21+00:00",
    "headline": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "url": "https://247wallst.com/investing/2025/12/08/lillys-glp-1-surge-dwarfs-abbotts-steady-device-growth-with-54-revenue-jump/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "727a145f-b93f-31c1-ba22-dd88c956f9a3",
      "content": {
        "id": "727a145f-b93f-31c1-ba22-dd88c956f9a3",
        "contentType": "STORY",
        "title": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
        "description": "",
        "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
        "pubDate": "2025-12-08T14:21:21Z",
        "displayTime": "2025-12-08T14:21:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/8b86802b1c9c8050aba5f86a6f0be591",
          "originalWidth": 1376,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FV7wVjrGww2ArYW6HH8NxA--~B/aD03Njg7dz0xMzc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/8b86802b1c9c8050aba5f86a6f0be591.cf.webp",
              "width": 1376,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9fLK0PUtXW9iK7OygiywEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/8b86802b1c9c8050aba5f86a6f0be591.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/08/lillys-glp-1-surge-dwarfs-abbotts-steady-device-growth-with-54-revenue-jump/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-glp-1-surge-dwarfs-142121955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:00:00+00:00",
    "headline": "Carolyn Bertozzi returns to Lilly board of directors",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.",
    "url": "https://finance.yahoo.com/news/carolyn-bertozzi-returns-lilly-board-150000194.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1eb2c50a-1112-3efa-8be6-59633acdac8b",
      "content": {
        "id": "1eb2c50a-1112-3efa-8be6-59633acdac8b",
        "contentType": "STORY",
        "title": "Carolyn Bertozzi returns to Lilly board of directors",
        "description": "",
        "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.",
        "pubDate": "2025-12-08T15:00:00Z",
        "displayTime": "2025-12-08T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/carolyn-bertozzi-returns-lilly-board-150000194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/carolyn-bertozzi-returns-lilly-board-150000194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T14:27:00+00:00",
    "headline": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
    "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
    "url": "https://www.investors.com/news/technology/kymera-therapeutics-nurix-therapeutics-stat6-degrader-dupixent/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e4eadc66-e1c4-303f-ae66-5862fa83f1fb",
      "content": {
        "id": "e4eadc66-e1c4-303f-ae66-5862fa83f1fb",
        "contentType": "STORY",
        "title": "Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?",
        "description": "",
        "summary": "Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.",
        "pubDate": "2025-12-08T14:27:00Z",
        "displayTime": "2025-12-08T14:27:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e4eadc66-e1c4-303f-ae66-5862fa83f1fb/kymera-rockets-pulling-nurix.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/09ba19f7022f728d820ba88f1e1c397d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uhx_9DI.WSXWi7NJFOtfMg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/09ba19f7022f728d820ba88f1e1c397d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QnR5UcB6oJOC5w0.Sp0p.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/09ba19f7022f728d820ba88f1e1c397d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/kymera-therapeutics-nurix-therapeutics-stat6-degrader-dupixent/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "NRIX"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:55:06+00:00",
    "headline": "Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug",
    "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
    "url": "https://www.investors.com/news/technology/structure-therapeutics-stock-weight-loss-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ea865bdb-4073-3e4d-b49c-e0d8900dd9cf",
      "content": {
        "id": "ea865bdb-4073-3e4d-b49c-e0d8900dd9cf",
        "contentType": "STORY",
        "title": "Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug",
        "description": "",
        "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
        "pubDate": "2025-12-08T15:55:06Z",
        "displayTime": "2025-12-08T15:55:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ea865bdb-4073-3e4d-b49c-e0d8900dd9cf/structure-therapeutics-soars-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8M36.DfkvFpQQpC7HaKRg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w9IRMeNSW5IkGlfVkdiIXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/structure-therapeutics-stock-weight-loss-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T14:45:04+00:00",
    "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144504980.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "39c30faf-8f86-3de0-b97b-b03cd76494a2",
      "content": {
        "id": "39c30faf-8f86-3de0-b97b-b03cd76494a2",
        "contentType": "STORY",
        "title": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
        "description": "",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "pubDate": "2025-12-08T14:45:04Z",
        "displayTime": "2025-12-08T14:45:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vqy2StQrekYiw3wwFUCZ6A--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N1J8mAJyPZolYBef44MAwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144504980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144504980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T16:34:00+00:00",
    "headline": "Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035",
    "summary": "Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's",
    "url": "https://finance.yahoo.com/news/neuroblastoma-market-global-regional-analysis-163400706.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d2dd9868-95ee-337f-ba73-13621414a405",
      "content": {
        "id": "d2dd9868-95ee-337f-ba73-13621414a405",
        "contentType": "STORY",
        "title": "Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035",
        "description": "",
        "summary": "Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's",
        "pubDate": "2025-12-08T16:34:00Z",
        "displayTime": "2025-12-08T16:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/neuroblastoma-market-global-regional-analysis-163400706.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/neuroblastoma-market-global-regional-analysis-163400706.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:53:00+00:00",
    "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
    "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
    "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f11c9697-fdcf-3435-9c72-3509bf095225",
      "content": {
        "id": "f11c9697-fdcf-3435-9c72-3509bf095225",
        "contentType": "STORY",
        "title": "Top-Ranked ETFs to Power Your Portfolio Higher",
        "description": "",
        "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
        "pubDate": "2025-12-08T15:53:00Z",
        "displayTime": "2025-12-08T15:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b",
          "originalWidth": 620,
          "originalHeight": 356,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nPZ_xEl63p_OAePi2f9LxQ--~B/aD0zNTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b.cf.webp",
              "width": 620,
              "height": 356,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QBGlpmygme_9thU3DtyI0w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/09147180af9fd4afaa322c5ac4332f4b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-ranked-etfs-power-portfolio-155300843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SHW"
            },
            {
              "symbol": "XLF"
            },
            {
              "symbol": "XLB"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NEM"
            },
            {
              "symbol": "NEMCL"
            },
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "V"
            },
            {
              "symbol": "XLK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:36:36+00:00",
    "headline": "Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill",
    "summary": "Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial.  The trial results raised hopes for high sales in the booming obesity-drug market.  Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-08-2025/card/structure-therapeutics-stock-jumps-on-trial-results-for-weight-loss-pill-5itGftLJ8NQQ1bXFv5Qz?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "489a83e4-78bc-362f-be82-d830d1ffc459",
      "content": {
        "id": "489a83e4-78bc-362f-be82-d830d1ffc459",
        "contentType": "STORY",
        "title": "Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill",
        "description": "",
        "summary": "Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial.  The trial results raised hopes for high sales in the booming obesity-drug market.  Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.",
        "pubDate": "2025-12-08T15:36:36Z",
        "displayTime": "2025-12-08T15:36:36Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/489a83e4-78bc-362f-be82-d830d1ffc459/structure-therapeutics-stock.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-08-2025/card/structure-therapeutics-stock-jumps-on-trial-results-for-weight-loss-pill-5itGftLJ8NQQ1bXFv5Qz?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T17:36:45+00:00",
    "headline": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]",
    "url": "https://finance.yahoo.com/news/guggenheim-maintains-buy-eli-lilly-173645473.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "dd04f88d-1085-3746-a3ac-8e1ffb94a6e7",
      "content": {
        "id": "dd04f88d-1085-3746-a3ac-8e1ffb94a6e7",
        "contentType": "STORY",
        "title": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]",
        "pubDate": "2025-12-08T17:36:45Z",
        "displayTime": "2025-12-08T17:36:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-maintains-buy-eli-lilly-173645473.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-maintains-buy-eli-lilly-173645473.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:55:06+00:00",
    "headline": "Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug",
    "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
    "url": "https://www.investors.com/news/technology/structure-therapeutics-stock-weight-loss-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ea865bdb-4073-3e4d-b49c-e0d8900dd9cf",
      "content": {
        "id": "ea865bdb-4073-3e4d-b49c-e0d8900dd9cf",
        "contentType": "STORY",
        "title": "Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug",
        "description": "",
        "summary": "Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.",
        "pubDate": "2025-12-08T15:55:06Z",
        "displayTime": "2025-12-08T15:55:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ea865bdb-4073-3e4d-b49c-e0d8900dd9cf/structure-therapeutics-soars-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8M36.DfkvFpQQpC7HaKRg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w9IRMeNSW5IkGlfVkdiIXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/e954c5b8aeb12f3ae9a32ea3ec992c8f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/structure-therapeutics-stock-weight-loss-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T19:05:00+00:00",
    "headline": "Lilly declares first-quarter 2026 dividend",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.",
    "url": "https://finance.yahoo.com/news/lilly-declares-first-quarter-2026-190500643.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "3eb63e49-a65f-3166-8143-de64ddb2324c",
      "content": {
        "id": "3eb63e49-a65f-3166-8143-de64ddb2324c",
        "contentType": "STORY",
        "title": "Lilly declares first-quarter 2026 dividend",
        "description": "",
        "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.",
        "pubDate": "2025-12-08T19:05:00Z",
        "displayTime": "2025-12-08T19:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-declares-first-quarter-2026-190500643.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-declares-first-quarter-2026-190500643.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T18:53:00+00:00",
    "headline": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
    "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
    "url": "https://finance.yahoo.com/news/cobenfy-become-growth-driver-bmys-185300541.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "503cd928-0eac-3549-9944-a9eb15bfb8ed",
      "content": {
        "id": "503cd928-0eac-3549-9944-a9eb15bfb8ed",
        "contentType": "STORY",
        "title": "Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?",
        "description": "",
        "summary": "Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.",
        "pubDate": "2025-12-08T18:53:00Z",
        "displayTime": "2025-12-08T18:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cobenfy-become-growth-driver-bmys-185300541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cobenfy-become-growth-driver-bmys-185300541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T17:46:00+00:00",
    "headline": "Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk",
    "summary": "Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.",
    "url": "https://www.barrons.com/articles/obesity-biotechs-structure-wave-lilly-novo-556ea734?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "389fa617-ad04-3fd6-ba53-4ba53d21cf0e",
      "content": {
        "id": "389fa617-ad04-3fd6-ba53-4ba53d21cf0e",
        "contentType": "STORY",
        "title": "Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk",
        "description": "",
        "summary": "Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.",
        "pubDate": "2025-12-08T17:46:00Z",
        "displayTime": "2025-12-08T17:46:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/389fa617-ad04-3fd6-ba53-4ba53d21cf0e/obesity-biotechs%E2%80%99-gains-hit.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/7fa778efec5a192c8e481b5db3796c92",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yUNTn0FWaenK46GxCjcRfA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/7fa778efec5a192c8e481b5db3796c92.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fg_VKn_h1ZsizpJyuyfA7w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/7fa778efec5a192c8e481b5db3796c92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/obesity-biotechs-structure-wave-lilly-novo-556ea734?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "WVE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]